![]() ![]() | Related Articles |
Fracture Fee, High quality of Life and Again Ache in Sufferers with Osteoporosis Handled with Teriparatide: 24-Month Outcomes from the Prolonged Forsteo Observational Research (ExFOS).
Calcif Tissue Int. 2016 Sep;99(three):259-71
Authors: Langdahl BL, Ljunggren Ö, Benhamou CL, Marin F, Kapetanos G, Kocjan T, Lespessailles E, Napoli N, Nikolic T, Petto H, Moll T, Lindh E
Summary
We describe the pre-planned interim evaluation of fracture outcomes, health-related high quality of life (HRQoL) and again ache in sufferers with extreme osteoporosis handled with teriparatide for as much as 24 months within the Prolonged Forsteo (Forsteo(®) is a registered commerce identify of Eli Lilly and Firm) Observational Research (ExFOS), a potential, multinational, observational research. Knowledge on incident medical fractures, HRQoL (EQ-5D questionnaire) and again ache [100 mm visual analogue scale (VAS)] had been collected. The variety of sufferers with fractures was summarised in 6-month intervals and fracture charge over every 6-month interval was assessed utilizing logistic regression for repeated measures. Modifications from baseline in EQ-5D and again ache VAS had been analysed utilizing blended fashions for repeated measures. Of 1454 sufferers within the energetic therapy cohort, 90.6 % had been feminine and 14.four % had been taking glucocorticoids. Throughout teriparatide therapy (median period 23.7 months), 103 sufferers (7.1 %) sustained a complete of 122 incident medical fractures (21 % vertebral, 79 % non-vertebral). A 49 % lower within the odds of fractures and a 75 % lower within the odds of medical vertebral fractures had been noticed within the >18- to 24-month interval versus the primary 6-month interval (each p < zero.05). EQ-5D scores and again ache VAS scores had been considerably improved from baseline at every post-baseline statement throughout teriparatide therapy. In conclusion, sufferers with extreme osteoporosis confirmed a major discount within the incident fracture charge throughout 24 months of teriparatide therapy in routine medical follow, accompanied by a major enchancment in HRQoL and discount in again ache. Outcomes needs to be interpreted within the context of the non-controlled design of this observational research.
PMID: 27137783 [PubMed – indexed for MEDLINE]